Application of formononetin in preparing medicine for treating breast cancer

A formononetin, anti-breast cancer technology, applied in the directions of drug combination, anti-tumor drugs, pharmaceutical formulations, etc., can solve the problems of high price, injury, many side effects, etc., achieve prevention and treatment of breast cancer, high development value and practical application significance, the effect of inhibiting the proliferation of breast cancer cells

Inactive Publication Date: 2013-11-20
GUILIN MEDICAL UNIVERSITY
View PDF3 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinically, surgical treatment, endocrine therapy and selective antagonist treatment of estrogen withdrawal, such as tamoxifen (Tamoxifen), raloxifene, etc., are often used as selective estrogen receptor antagonists. In addition to tumor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of formononetin in preparing medicine for treating breast cancer
  • Application of formononetin in preparing medicine for treating breast cancer
  • Application of formononetin in preparing medicine for treating breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1: Effect of formononetin on proliferation of human breast cancer cell MCF-7.

[0031] MCF-7 cells were digested and counted, 4×10 per well 3 Cells were seeded into 96-well cell culture plates and placed at 37°C, 5% CO 2 Incubate the culture in the incubator. After 24 hours, replace with the culture medium containing formononetin at final concentrations of 0, 10, 20, 30, 40, 60, 80, 100 μM, and set 3 parallel wells for each concentration. Observe the cell morphology under a microscope, add MTT solution (5mg / mL), incubate at 37°C for 4 hours, shake for 10min in the dark, and detect the absorbance (OD) value of each well at a wavelength of 570nm with a Bio-Rad enzyme-linked immunosorbent detector.

[0032] MTT results showed that formononetin could inhibit the proliferation of MCF-7 cells in a dose-dependent manner. Among them, when the drug concentration was 100 μM, the inhibitory effect was the most obvious. Compared with the blank control, the inhibitory rat...

Embodiment 2

[0033] Example 2: Effect of formononetin on cell cycle of human breast cancer cell MCF-7

[0034] Collect human breast cancer MCF-7 cells in the logarithmic growth phase, adjust the cell concentration to 1×10 6 cells were seeded into 6-well plates. After the cells adhered to the wall, add different concentrations of formononetin (20, 40, 80 μM), continue to culture for 48 hours, collect the cells in each group, wash twice with pre-cooled PBS, and fix with 70% ethanol at 4°C overnight , stained with propidium iodide (PI) (50 μg / ml) at room temperature in the dark, and after 15 minutes, the cell cycle was detected by flow cytometry. The result is as figure 2 with image 3 shown.

[0035] Depend on figure 2 with image 3 It can be seen that formononetin has obvious cell cycle arrest effect on human breast cancer cell MCF-7. The G0 / G1 phase of the cells in the blank group was 42%, the S phase was 33%, and the G2 / M phase was 25%. The cells treated with different concentrat...

Embodiment 3

[0036] Example 3: Western Blot detection of formononetin on human breast cancer MCF-7 cell IGF1 / IGF1R-PI3K / AKT-Cyclin D1 pathway changes

[0037] They were treated with culture solution containing 20, 40, and 80 μM formononetin for 48 hours, and 0.1% DMSO was used as a blank control. Wash with PBS, digest and lyse the cells with RIPA lysate containing protease inhibitors, centrifuge at 4°C for 20 min, take the supernatant, and measure the protein concentration. Add 5X loading buffer and heat at 95°C for 5 minutes to prepare the sample to be tested. After the above protein samples were separated by SDS-PAGE electrophoresis, they were transferred to PVDF membranes. The membrane was blocked with 5% skim milk in TBST solution for 1 h at room temperature. The membrane was placed in 5% skimmed milk TBST containing primary antibody and incubated overnight at 4°C, and the dilution of primary antibody (IGF1R, p-IGF1R, AKT, p-AKT, Cyclin D1) was 1:1000. The membrane was washed 3 time...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a novel use of formononetin in pharmacy, and in particular discloses an application of formononetin in preparing a medicine for treating breast cancer. The applicants discover that formononetin can remarkably inhibit cell proliferation of breast cancer for the first time and discover through experiments that formononetin retards cell cycle by way of inactivating IGF1/IGF1R-PI3K/AKT, so that formononetin generates good activity of inhibiting cell proliferation of breast cancer, and can be used as a cell cycle retardant to replace tamoxifen to inhibit cell proliferation of breast cancer so as to prevent and treat breast cancer. In addition, the applicants in experiments further discover that formononetin can be used as the cycle retardant for cancer cells and has specific targeting to normal cells as an agonist, so that formononetin has very high development value and real application value.

Description

technical field [0001] The invention relates to the application of a Chinese herbal medicine monomer, in particular to the application of formononetin in the preparation of anti-breast cancer drugs. Background technique [0002] Breast cancer is one of the most common cancers in adult women, especially in developed countries in Europe and America, breast cancer patients can reach about 30% of all adult female cancer patients. my country used to be one of the countries with a low incidence of breast cancer. However, in the past two decades, with the rapid economic growth, people's diet structure and lifestyle have undergone great changes. The incidence of breast cancer is higher than that of female population. Especially among urban women, there is an explosive growth. Clinically, surgical treatment, endocrine therapy and selective antagonist treatment of estrogen withdrawal, such as tamoxifen (Tamoxifen), raloxifene, etc., are often used as selective estrogen receptor antago...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61P35/00
Inventor 陈健田晶叶雨张幸李政钊王文波
Owner GUILIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap